Codexis, Inc.

CDXS

바이오테크·제약

$1.66vs prev close▼-0.01(-0.55%)

$0.9652W Range$2.98

35% from low

+0.19 (+12.84%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.08%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -100.0% · Market value -100.0% · Weight -0.08%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
23.08.31	SELL	ARKG	92	$1.74	$160
23.08.30	SELL	ARKG	572	$1.76	$1.0K
23.08.29	SELL	ARKG	8,500	$1.79	$15.2K
23.08.28	SELL	ARKG	110,596	$1.69	$186.9K
23.08.23	SELL	ARKG	599,478	$1.79	$1.1M
23.08.22	SELL	ARKG	249,538	$1.76	$439.2K
23.08.21	SELL	ARKG	249,538	$1.73	$431.7K
23.08.18	SELL	ARKG	1,416,591	$1.66	$2.4M
23.08.17	SELL	ARKG	62,411	$1.69	$105.5K
23.08.15	SELL	ARKG	26,560	$1.84	$48.9K
23.08.14	SELL	ARKG	90,723	$1.97	$178.7K
23.08.11	SELL	ARKG	175,416	$2.09	$366.6K
23.08.10	SELL	ARKG	183,333	$2.13	$390.5K
23.08.09	SELL	ARKG	115,956	$2.19	$253.9K
23.08.08	SELL	ARKG	141,647	$2.29	$324.4K

08.31SELL

ARKGClose$1.74Est. total$160

08.30SELL

572

ARKGClose$1.76Est. total$1.0K

08.29SELL

8,500

ARKGClose$1.79Est. total$15.2K

08.28SELL

110,596

ARKGClose$1.69Est. total$186.9K

08.23SELL

599,478

ARKGClose$1.79Est. total$1.1M

08.22SELL

249,538

ARKGClose$1.76Est. total$439.2K

08.21SELL

249,538

ARKGClose$1.73Est. total$431.7K

08.18SELL

1,416,591

ARKGClose$1.66Est. total$2.4M

08.17SELL

62,411

ARKGClose$1.69Est. total$105.5K

08.15SELL

26,560

ARKGClose$1.84Est. total$48.9K

08.14SELL

90,723

ARKGClose$1.97Est. total$178.7K

08.11SELL

175,416

ARKGClose$2.09Est. total$366.6K

08.10SELL

183,333

ARKGClose$2.13Est. total$390.5K

08.09SELL

115,956

ARKGClose$2.19Est. total$253.9K

08.08SELL

141,647

ARKGClose$2.29Est. total$324.4K

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

0 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

Est. Sold Value

$161.92

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$6.33

vs Current ▲ +279.2% upside

Current$1.67

Low ~ High$2.00 ~ $11.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Piper Sandler

Overweight

$8.00

+379.04%

—

Maintain

2026-08-17

Cantor Fitzgerald

Overweight

$11.00

+558.68%

—

Maintain

2024-11-22

Cantor Fitzgerald

Overweight

$11.00

+558.68%

—

Maintain

2024-11-15

Benchmark

Hold

N/A

—

Maintain

2024-11-04

Cantor Fitzgerald

Overweight

$11.00

+558.68%

—

Maintain

2024-09-20

1 / 4

Avg Target

$6.33

vs Current ▲ +279.2% upside

Buy

7 analysts

Strong Buy 1Buy 4Hold 2

Low $2.00

Current $1.67

High $11.00

Firm	Position	Target	Upside	Close	Action	Date
Piper Sandler	Overweight	$8.00	+379.04%	—	Maintain	26.08.17
Cantor Fitzgerald	Overweight	$11.00	+558.68%	—	Maintain	24.11.22
Cantor Fitzgerald	Overweight	$11.00	+558.68%	—	Maintain	24.11.15
Benchmark	Hold	N/A	N/A	—	Maintain	24.11.04
Cantor Fitzgerald	Overweight	$11.00	+558.68%	—	Maintain	24.09.20

1 / 4

Price Information

Previous Close$1.67

Open$1.60

Day Range$1.58 - $1.70

52-Week Range$0.96 - $2.98

1-Year Change-37.69%

Trading Volume

Volume1,257,998

Avg Volume (3mo)1,143,720

Valuation

Market Cap182.9M

Book Value$0.36

Shares Outstanding109,505,765

Financials

Revenue (TTM)77.7M

Net Income-30,723,000

EPS$-0.33

EBITDA-19,047,000

Profitability

P/E Ratio-

P/B Ratio4.63

Return on Equity (ROE)-69.36%

Return on Assets (ROA)-11.74%

Profit Margin-39.55%

EV/EBITDA-10.53

Beta2.50

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)67.74

Company Overview

Codexis, Inc. is a biotechnology company that develops and manufactures enzymatic solutions for the pharmaceutical industry, particularly for therapeutics manufacturing. Their proprietary CodeEvolver technology platform enables the discovery and enhancement of novel enzymes, and they also offer the ECO Synthesis platform for scaled RNAi therapeutic manufacturing. Codexis operates globally, serving markets in North America, Europe, Asia, and beyond.

P/B

4.63

High valuation

ROE

-69.4%

Persistent loss

Beta

2.50

Extreme volatility

RSI(14)

67.7

Neutral zone

AI-generated summary. Not investment advice.

Codexis, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks